46 results
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
to treatments and a cure for FA FARA provides industry with several key items Assistance with patient recruitment and education Access to Global
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
with patient recruitment and education Access to Global Patient Registry with demographic and clinical information on more than 1,000 FA patients
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
recruitment and retention of exceptional officer candidates that conclude that the potential exposure to liabilities, costs of defense and other risks
8-K
EX-99.2
04bg6yr5
11 Mar 24
Other Events
4:09pm
424B5
suyddomjoq3uc0cy
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
09asyxb 8hcip1
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.2
fw9l8uckhpbsu8zmy
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
rgqqrrcq2vrav69wd
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
xk7jamlzlrjotzg9w
14 Aug 23
Other Events
8:00am
8-K
EX-99.1
sc7aq4f 4az2
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
EX-99.2
8h5ez9rq1halqsrvzb
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
pskocvqn xm1e
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am